ABSTRACT
BACKGROUND AND OBJECTIVES:
Cannabis is the most popular and consumed illicit drug in the world, it has about 540 bioactive phytocannabinoids, including tetrahydrocarbinol (THC) and cannabidiol (CBD). The therapeutic potential of phytocannabinoids has been the subject of many studies in recent decades for many medical situations, including the management of chronic pain. The advent of pharmacogenetics currently allows the indication of the Cannabis dose to be evaluated individually. The objective of this work was to carry out a survey of the literature on the medicinal use of Cannabis and the application of pharmacogenetics in this therapy.
CONTENTS:
THC and CBD phytocannabinoids are the most abundant and researched. In the endocannabinoid system there are compounds similar to phytocannabinoids, cell receptors and metabolism enzymes. All these molecules are secreted from genes, which may have individual genetic polymorphisms that determine the modulation of the endocannabinoid system, and consequently impact the patients’ therapeutic response.
CONCLUSION:
The existence of genetic tests for the prior assessment of the patients genetic profile in order to avoid side effects and to have more assertiveness in the indication of the cannabis product is an important tool to increase adherence to cannabis treatment.
Keywords
Cannabis; Genetic variation; Medical marijuana; Pharmacogenetics; Polymorphism; Single nucleotide
HIGHLIGHTS
-
There are questions about adverse effects and risk of addiction associated with cannabis use.
-
Evaluation of genetic polymorphisms related to cannabis use is a reality.
-
Pharmacogenetics allows assertiveness in cannabis prescribing.